Kleiner Perkins leads $ 130 million in the Cinbase’s founder antiaging startup, Newlimit

Near the dawn of the twentieth century, human life expectancy began to jump significantly thanks to new scientific views on issues such as hand washing, vaccines and food safety. In recent decades, however, expected lives have been silver or even declined. Coinbase CEO Brian Armstrong believes that this situation can be reversed and says that a health startup he co -founded is making faster than planned progress by repairing cells in order to create longer and better lives.

Tuesday, this startup—Newlylim– He raised a round of $ 130 million series directed by the Kleiner Perkins Risk Capital Giant with contributions of new and existing investors, including Khosla Ventures and Founders Fund.

In an interview with Fortune, Armstrong explained that Newlimit’s research is based on a relatively new scientific field known as epigenetic reprogramming capable of manipulating cells in order to restore them to a younger or healthier state. These efforts focus on activating or deactivating features that pre -exist in various cells, and Armstrong says that the startup has already pointed out some notable hits.

In particular, he cited Newlimit’s advances in the restoration of cells connected to the body’s immune and immune system. The next phase, according to Armstrong, will be to identify dozens of additional areas where the startup research seems especially promising and then pouring significant funding into one or two of them.

“The Moonshot of this company would be a medicine to restore dozens of cell types,” he adds that he considers this emerging branch of epigenetics as an opportunity for trillions of dollars.

Armstrong also explained that artificial intelligence and a technique called unicellular cell sequencing have played a critical role in helping Newlimit to make quick advances in his research. In particular, according to him, these tools have allowed the startup to carry out a large number of test projections for a cents test.

From its current research rate, Newlimit plans to start trying treatments on non -human primates in the coming year or two, and then request approval to begin human tests by 2028.

“ Pushing the boundaries of human life and health health is an incredibly ambitious goal and has the potential to improve everyone’s life on the planet. Aparellating the genomic climbing with Frontier Ai, Newlimit is accelerating the advances at a rate that the field has not seen before, ” said Ilya Fushman, a couple by Kleiner Perkins, in a story.

Does the longest human life encompass?

The idea of ​​using technology to reverse aging and expanding life has gained popularity with a large segment of Silicon Valley. Other companies that support the B -series for Newlimit, which Armstrong launched after selling 2% of their Coinbase farms, along with the geneticists Blake Byers and Jacob Kimmel, include human capital and size capital. The round also attracted investments by prominent angels such as Elad Gil, Garry Tan, John and Patrick Collison, Joshua Kushner, Joe Lonsdale and Fred Ehrsam.

If startups like Newlimit manage to reverse harmful aging processes in certain key cells, the result can be a large number of people who no longer occur to conditions leading to chronic diseases or early mortality and a longer and better quality of life.

Of course, the perspective of the world population that lives more than in the past is full. This development would raise great issues on how societies would pay for their citizens to live longer, but also on how to create a political and social order to support a longer life. Armstrong acknowledges that these considerations will be more pressing if Newlimit is successful as they expect, but that the questions are larger than the startup can be addressed.

For now, Armstrong says, Newlimit focuses on helping to build medical and health infrastructure to expand human life.

“In the last 50 years, longevity has been raised,” he says. “We folded it once before, why can’t we bend again?”

This story originally presented to Fortune.com